Literature DB >> 27379986

Quantitative Analysis of [18F]FMISO PET for Tumor Hypoxia: Correlation of Modeling Results with Immunohistochemistry.

Kuangyu Shi1, Christine Bayer2, Sabrina T Astner2, Florian C Gaertner3, Peter Vaupel2, Markus Schwaiger3, Sung-Cheng Huang4, Sibylle I Ziegler3.   

Abstract

PURPOSE: Quantitative evaluation of tumor hypoxia based on H-1-(3-[18F]fluoro-2-hydroxypropyl)-2-nitroimidazole ([18F]FMISO) positron emission tomography (PET) can deliver important information for treatment planning in radiotherapy. However, the merits and limitations of different analysis methods in revealing the underlying physiological feature are not clear. This study aimed to assess these quantitative analysis methods with the support of immunohistological data. PROCEDURES: Sixteen nude mice bearing xenografted human squamous cell carcinomas (FaDu or CAL-33) were scanned using 2-h dynamic [18F]FMISO PET. Tumors were resected and sliced, and the hypoxia marker pimonidazole was immunostained followed by H&E staining. The pimonidazole signal was segmented using a k-means clustering algorithm, and the hypoxic fraction (HF) was calculated as the hypoxic area/viable tumor-tissue-area ratio pooled over three tissue slices from the apical, center, and basal layers. PET images were analyzed using various methods including static analysis [standard uptake value (SUV), tumor-to-blood ratio (T/B), tumor-to-muscle ratio (T/M)] and kinetic modeling (Casciari αk A , irreversible and reversible two-tissue compartment k 3, Thorwarth w A k 3, Patlak K i , Logan V d , Cho K), and correlated with HF.
RESULTS: No significant correlation was found for static analysis. A significant correlation between k 3 of the irreversible two-tissue compartment model and HF was observed (r = 0.61, p = 0.01). The correlation between HF and αk A of the Casciari model could be improved through reducing local minima by testing more sets of initial values (r = 0.59, p = 0.02) or by reducing the model complexity by fixing three parameters (r = 0.63, p = 0.0008).
CONCLUSIONS: With support of immunohistochemistry data, this study shows that various analysis methods for [18F]FMISO PET perform differently for assessment of tumor hypoxia. A better fitting quality does not necessarily mean a higher physiological correlation. Hypoxia PET analysis needs to consider both the mathematical stability and physiological fidelity. Based on the results of this study, preference should be given to the irreversible two-tissue compartment model as well as the Casciari model with reduced parameters.

Entities:  

Keywords:  Dynamic PET; Fmiso; Pharmacokinetic modeling; Tumor hypoxia

Mesh:

Substances:

Year:  2017        PMID: 27379986     DOI: 10.1007/s11307-016-0975-4

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  40 in total

1.  Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI.

Authors:  Piet Dirix; Vincent Vandecaveye; Frederik De Keyzer; Sigrid Stroobants; Robert Hermans; Sandra Nuyts
Journal:  J Nucl Med       Date:  2009-06-12       Impact factor: 10.057

2.  Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole.

Authors:  W J Koh; J S Rasey; M L Evans; J R Grierson; T K Lewellen; M M Graham; K A Krohn; T W Griffin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

3.  Comparison of (immuno-)fluorescence data with serial [¹⁸F]Fmiso PET/CT imaging for assessment of chronic and acute hypoxia in head and neck cancers.

Authors:  Constantin-Alin Maftei; Kuangyu Shi; Christine Bayer; Sabrina T Astner; Peter Vaupel
Journal:  Radiother Oncol       Date:  2011-06-28       Impact factor: 6.280

4.  Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker.

Authors:  J A Raleigh; D P Calkins-Adams; L H Rinker; C A Ballenger; M C Weissler; W C Fowler; D B Novotny; M A Varia
Journal:  Cancer Res       Date:  1998-09-01       Impact factor: 12.701

5.  18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors.

Authors:  Christoph Oehler; Joseph A O'Donoghue; James Russell; Pat Zanzonico; Sylvie Lorenzen; C Clifton Ling; Sean Carlin
Journal:  J Nucl Med       Date:  2011-02-14       Impact factor: 10.057

6.  Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.

Authors:  Susanne-Martina Eschmann; Frank Paulsen; Matthias Reimold; Helmut Dittmann; Stefan Welz; Gerald Reischl; Hans-Juergen Machulla; Roland Bares
Journal:  J Nucl Med       Date:  2005-02       Impact factor: 10.057

7.  pO(2) Polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2'-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia.

Authors:  Bernd Gagel; Patrick Reinartz; Ercole Dimartino; Michael Zimny; Michael Pinkawa; Payam Maneschi; Sven Stanzel; Kurt Hamacher; Heinz H Coenen; Michael Westhofen; Ulrich Büll; Michael J Eble
Journal:  Strahlenther Onkol       Date:  2004-10       Impact factor: 3.621

Review 8.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review.

Authors:  P Vaupel; F Kallinowski; P Okunieff
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

9.  Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia.

Authors:  HyungJoon Cho; Ellen Ackerstaff; Sean Carlin; Mihaela E Lupu; Ya Wang; Asif Rizwan; Joseph O'Donoghue; C Clifton Ling; John L Humm; Pat B Zanzonico; Jason A Koutcher
Journal:  Neoplasia       Date:  2009-03       Impact factor: 5.715

10.  A modeling approach for quantifying tumor hypoxia with [F-18]fluoromisonidazole PET time-activity data.

Authors:  J J Casciari; M M Graham; J S Rasey
Journal:  Med Phys       Date:  1995-07       Impact factor: 4.071

View more
  3 in total

1.  Changes in Tumor Biology During Chemoradiation of Cervix Cancer Assessed by Multiparametric MRI and Hypoxia PET.

Authors:  Petra Georg; Piotr Andrzejewski; Pascal Baltzer; Michaela Daniel; Wolfgang Wadsak; Markus Mitterhauser; Alina Sturdza; Katarina Majercakova; Georgios Karanikas; Richard Pötter; Marcus Hacker; Thomas Helbich; Dietmar Georg; Katja Pinker
Journal:  Mol Imaging Biol       Date:  2018-02       Impact factor: 3.488

2.  [18F]Fluoromisonidazole PET in rectal cancer.

Authors:  Tanuj Puri; Tessa A Greenhalgh; James M Wilson; Jamie Franklin; Lia Mun Wang; Victoria Strauss; Chris Cunningham; Mike Partridge; Tim Maughan
Journal:  EJNMMI Res       Date:  2017-09-20       Impact factor: 3.138

3.  Hypoxia and perfusion in breast cancer: simultaneous assessment using PET/MR imaging.

Authors:  Julia C Carmona-Bozo; Roido Manavaki; Ramona Woitek; Turid Torheim; Gabrielle C Baxter; Corradina Caracò; Elena Provenzano; Martin J Graves; Tim D Fryer; Andrew J Patterson; Fiona J Gilbert
Journal:  Eur Radiol       Date:  2020-07-28       Impact factor: 5.315

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.